Abstract-Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, nϭ5; 5 ng ⅐ kg Ϫ1 ⅐ min
ndothelins (ETs) are 21-amino acid peptides that act as modulators of coronary vasomotor tone. 1 There are two distinct receptors for ET, ETA and ETB, each encoded by a different gene. 2, 3 The ETA receptor is expressed in vascular smooth muscle, whereas the ETB receptor is localized to endothelial and smooth muscle cells. 4 Coronary vasoconstriction is mediated by both receptors. 1 We 5 recently reported that intracoronary infusion of ET-1 at pathophysiological concentrations results in coronary epicardial vasoconstriction in dogs, which was presumed to be mediated predominantly via the ETA receptor.
Hypercholesterolemia is a pathophysiological state characterized by impaired coronary endothelium-dependent arterial relaxation to the endothelium-dependent vasodilator acetylcholine. 6, 7 In a porcine model of diet-induced hypercholesterolemia, plasma concentrations of ET are elevated, and coronary tissue ET immunoreactivity is enhanced. 8 Moreover, intracoronary infusion of acetylcholine causes vasoconstriction and further increases plasma ET concentrations. 8 Similarly, humans with coronary endothelial dysfunction have enhanced ET immunoreactivity in the coronary circulation, with an additional rise in coronary ET levels during intracoronary infusion of acetylcholine. 9 These prior studies implicate ET as a potential mediator of endothelial dysfunction in hypercholesterolemia, possibly through stimulation of the ET receptor. The present study was designed to examine the hypothesis that selective inhibition of the ET receptor attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia.
Methods

Animals and Instrumentation
The following studies were performed after approval by the Mayo Clinic Institutional Animal Care and Use Committee. All experiments were conducted using juvenile domestic crossbred pigs, each weighing 25 to 37 kg. In phase I, we verified that intracoronary infusion of FR-139317, a selective ETA receptor antagonist, 10 inhibits the coronary vasoconstrictor response elicited by ET-1 after 10 weeks of high-cholesterol diet, in light of previous in vitro studies that have alluded to an increased vasoconstrictor response to ET in pathophys-iological states, such as hypercholesterolemia and atherosclerosis. 11 In phase II, we examined the effect of intracoronary infusion of FR-139317 before intracoronary acetylcholine on coronary artery diameter in the steady state and after 10 weeks of diet-induced hypercholesterolemia. In phase III, we examined the effect of intracoronary infusion of the nonselective ET-receptor antagonist bosentan 12 before intracoronary acetylcholine on coronary artery diameter in the steady state and after 10 weeks of diet-induced hypercholesterolemia. In phase IV, we further examined the role of the ETB receptor in the coronary epicardial vasoconstrictor to ETs at baseline and after 10 weeks of high-cholesterol diet.
Each animal was fasted overnight before the day of the study but allowed ad libitum access to tap water. Animals were initially anesthetized with ketamine 30 mg/kg IM and xylazine 5 mg/kg IM, and additional anesthesia was given using a titrated intravenous infusion of a solution containing ketamine (5 g/L) and xylazine (7.5 mg/L) to maintain a constant level of anesthesia. The external or internal jugular vein was exposed by cutdown and cannulated with a 7F venous sheath. A flow-directed thermodilution catheter was advanced through the venous sheath for the measurement of PAP, PCWP, and CO. The external carotid artery was also exposed by cutdown and cannulated with an 8F arterial sheath. After injecting 10 000 U of heparin intravenously (followed by intravenous infusion of 1000 U of heparin per hour), an 8F Judkins left coronary guiding catheter was used to engage the left main coronary artery. A 2.2F coronary-infusion catheter (Ultrafuse, SciMed Life System) was advanced over a guidewire and positioned into the proximal portion of the left anterior descending coronary artery. All infusions (see below) were delivered at a rate of 1 mL/min through the coronary infusion catheter. MAP and HR were continuously monitored throughout the procedure. Arterial blood samples for lipid profile 13 and circulating ET 8, 9 were obtained before each procedure. After the baseline study, all animals were placed on a diet of 2% cholesterol and 15% lard by weight (TD 93296, Harlan Teklad) for 10 weeks. The respective studies were repeated in their entirety at 10 weeks.
Study Groups
Phase I
The animals were divided into two groups: ET-1 infusion (group I, nϭ5) and FR-139317 infusion followed by ET-1 infusion (group II, nϭ6). In pilot studies designed to determine the optimal dosage of ET, we found that intracoronary infusion of ET-1 (Peninsula Laboratories) at a rate of 2.5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 did not cause significant coronary epicardial vasoconstriction, whereas at a rate of 10 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 , there was severe vasoconstriction. When ET-1 was administered at a rate of 5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 , moderate coronary epicardial vasoconstriction was achieved. In group I, normal saline was given by intracoronary infusion for 20 minutes, followed by coinfusion with ET-1 for 30 minutes. In group II, FR-139317 (Abbott Laboratories) was infused at 5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for 20 minutes before coinfusion with ET-1. This dosage for FR-139317 was derived from previous studies performed in vivo in dogs. 5, 14 The following parameters were measured at baseline (P1), after 20 minutes of either normal saline or FR-139317 (P2), and after an additional 30 minutes of coinfusion of either normal saline or FR-139317 with ET-1 (P3): HR, MAP, PAP, PCWP, and CO (average of three measurements). At each time interval, systemic vascular resistance was calculated using the formula Systemic Vascular ResistanceϭMAP/CO. Also at each time interval, coronary angiography was performed with the use of nonionic contrast medium (Omnipaque, Winthrop Laboratories) after the hemodynamic measurements had been taken. The angles, skew rotation, and table height were kept constant during the procedure and were used again during the study at 10 weeks. CAD was measured by an independent investigator blinded to the drug infused, using a computer-based image-analysis system, as previously described and validated. 15, 16 The left anterior descending coronary artery was divided into three segments: proximal, middle, and distal. For each segment, the measurements were performed in the region where the greatest change had occurred. For each time interval, the diameter refers to the mean of the three segments.
Phase II
The animals were divided into two groups: control (group III, nϭ7) and FR-139317 (group IV, nϭ6). In group III, normal saline was given by intracoronary infusion for 20 minutes, followed by coinfusion of normal saline and acetylcholine. Group IV received FR-139317 at 5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for 20 minutes, followed by coinfusion of FR-139317 and acetylcholine. Acetylcholine (Iolab Pharmaceuticals), at concentrations of 10 Ϫ6 , 10 Ϫ5 , and 10 Ϫ4 mol/L (to achieve estimated final blood concentrations in the coronary bed of 10
Ϫ8
, 10
Ϫ7
, and 10
Ϫ6 mol/L, assuming coronary blood flow of 80 mL/min), was infused for 3 minutes at each concentration, as previously described. 9, 17 The same measurements described above for phase I were performed at the following time intervals: baseline (P1), after 20 minutes of infusion of either normal saline or FR-139317 (P2), and after coinfusion of either normal saline or FR-139317 with each dose of acetylcholine. Results are presented for each dose of acetylcholine, as well as for the highest dose of acetylcholine administered (P3).
Phase III
In this phase, the response to acetylcholine was examined in animals (group V, nϭ5) receiving bosentan (Ro 47-0203, intracoronary bolus of 0.5 mg/kg followed by an infusion at 1 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 ; Hoffman La Roche) at baseline and after 10 weeks of high-cholesterol diet. The same measurements described above for phase I were performed at the following time intervals: baseline (P1), after 20 minutes of infusion of bosentan (P2), and after coinfusion of bosentan with each dose of acetylcholine. Results are presented for each dose of acetylcholine, as well as for the highest dose of acetylcholine administered (P3). In preliminary experiments, we examined the systemic hemodynamic effects of bosentan at different doses; after an intracoronary bolus of 0.5 mg/kg, bosentan was given by intracoronary infusion at 0.1, 1, and 5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 for 20 minutes at each dose. At 1 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 , bosentan caused mild systemic hypotension (Ϸ10% reduction in MAP), whereas at 5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 , it reduced MAP by Ͼ20%. We thus elected to infuse bosentan at 1 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 in phase III. In addition, bosentan at this dose significantly attenuated the severe vasoconstrictor response to 5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ET-1 in two animals after 10 weeks of high-cholesterol diet (reduction in CAD of only 4Ϯ1%).
Phase IV
In this phase, we examined the coronary epicardial vasoconstrictor response to the ETB-receptor agonist S6c 18 at baseline and after 10 weeks of high-cholesterol diet. S6c (Phoenix Pharmaceuticals) was infused at 5 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 (ie, same dose as ET-1 infusion in phase I) through the coronary infusion catheter in four pigs at baseline and after 10 weeks of high-cholesterol diet. The same measurements described above for phase I were performed at the following time intervals: at baseline (P1), after 20 minutes of normal saline infusion (P2), and after 30 minutes of coinfusion of normal saline and S6c (P3).
Selected Abbreviations and Acronyms
CAD ϭ coronary artery diameter CO ϭ cardiac output ET ϭ endothelin HR ϭ heart rate MAP ϭ mean arterial pressure P1 ϭ first (baseline) measurement P2 ϭ second measurement P3 ϭ third measurement PAP ϭ pulmonary artery pressure PCWP ϭ pulmonary capillary wedge pressure S6c ϭ sarafotoxin 6c 
Statistics
Results
Lipid Profile
Plasma total cholesterol levels were significantly higher in animals fed a high-cholesterol diet than in pigs that were given a normal diet (376Ϯ24 versus 95Ϯ4 mg/dL; PϽ.0001). The increase in total plasma cholesterol levels could be attributed primarily to elevated LDL levels (289Ϯ15 versus 45Ϯ5 mg/ dL; PϽ.0001), although HDL levels were also higher (79Ϯ5 versus 48Ϯ2 mg/dL; PϽ.0001).
ET Levels
Circulating ET levels were significantly higher after 10 weeks of high-cholesterol diet compared with baseline (13.5Ϯ1.2 versus 6.2Ϯ0.8 pg/mL; PϽ.05).
Hemodynamics and Coronary Artery Diameter
There were no significant differences in systemic hemodynamic parameters between the six groups at baseline or at 10 weeks before drug infusion.
Phase I
Intracoronary ET-1 infusion at baseline did not affect MAP significantly (94Ϯ6 mm Hg at P1 versus 91Ϯ6 mm Hg at P3; PϭNS). Similarly, at 10 weeks, MAP was preserved (109Ϯ4 mm Hg at P1 versus 107Ϯ5 mm Hg at P3; PϭNS). Hemodynamic parameters measured at baseline and at 10 weeks were not affected differently by infusion of FR-139317 or normal saline before and during intracoronary infusion of ET-1 (data not shown). As shown in the Figure, 
Phase II
Systemic hemodynamic parameters measured at baseline and at 10 weeks were not affected differently by infusion of FR-139317 or normal saline before and during infusion of acetylcholine (Table  1) . At baseline, intracoronary infusion of FR-139317 for 20 minutes resulted in a slight increase in CAD (5Ϯ1%), which was comparable to the effect attained with normal saline infusion (3Ϯ2%; PϭNS). Coinfusion of FR-139317 and acetylcholine resulted in an additional 7Ϯ3% increase in CAD, which was not significantly different from the effect achieved with coinfusion of normal saline and acetylcholine (5Ϯ2%; PϭNS) ( Table 2 and Fig  1) . At 10 weeks, CAD was affected similarly by a 20-minute infusion of normal saline and FR-139317 (4Ϯ3% and 2Ϯ1% increase in CAD with normal saline and FR-139317, respectively; PϭNS). Likewise, FR-139317 coinfusion did not affect the vasoconstrictor response to acetylcholine infusion (23Ϯ12% and 19Ϯ7% reduction in CAD with coinfusion of normal saline and FR-139317, respectively; PϭNS) ( Table 2 and Fig 1) .
Phase III
In phase II, we demonstrated the lack of inhibition of acetylcholine-induced coronary epicardial vasoconstriction by FR-139317, a selective ETA-receptor antagonist. In phase III, we aimed to examine whether the intracoronary administration of bosentan, a combined ETA-and ETB-receptor antagonist, at the highest tolerated dose (ie, without untoward hemodynamic effects) would attenuate the vasoconstrictive effects of acetylcholine. Intracoronary infusion of bosentan alone did not affect CAD at baseline (2Ϯ5%) and 10 weeks (0Ϯ1%). MAP decreased by 11.4%Ϯ3.6% at baseline and 2.6Ϯ3.8% at 10 weeks (PϭNS for comparison of baseline versus 10 weeks). HR increased with bosentan infusion at baseline (17.8Ϯ5.8%) and 10 weeks (5.0Ϯ4.4%), with nonsignificant changes in CO and PAP. The coinfusion of bosentan and acetylcholine did not affect the response to acetylcholine at baseline (increase in CAD of 0Ϯ4% with bosentan versus 5Ϯ2% with acetylcholine alone, PϭNS) or at 10 weeks (decrease in CAD of 30Ϯ19% with bosentan versus 23Ϯ12% with acetylcholine alone; PϭNS) ( Table 2) . There was no significant difference in the response to 10 Ϫ4 mol/L acetylcholine among animals receiving normal saline (group III), FR-139317 (group IV), or bosentan (group V) either at baseline (Pϭ.29) or at 10 weeks (Pϭ.92).
Phase IV
In phase IV, intracoronary infusion of S6c, a selective ETBreceptor agonist, at the same dose of ET-1 infused in phase I, caused only a mild coronary epicardial vasoconstrictor response both at baseline and after 10 weeks of high-cholesterol diet (decrease in CAD of 10Ϯ2% and 12Ϯ3% at baseline and after 10 weeks, respectively). In contrast to the enhanced response to ET-1 after 10 weeks of high-cholesterol diet observed in phase I, the response to S6c was not enhanced. Both at baseline and at 10 weeks, S6c infusion did not significantly affect systemic hemodynamics (data not shown).
Discussion
The results of the present studies demonstrate that experimental hypercholesterolemia in the pig resulted in a coronary epicardial vasoconstrictor response to the endothelium-dependent vasodilator acetylcholine, as well as an enhanced coronary epicardial vasoconstrictor response to ET-1. Selective ETB-receptor stimulation by S6c at pathophysiological concentrations resulted in only a mild coronary epicardial vasoconstrictor response that was not affected by 10 weeks of high-cholesterol diet, suggesting that the enhanced coronary epicardial vasoconstrictor response to ET-1 in hypercholesterolemia is primarily mediated by non-ETB receptors. Indeed, the short-term intracoronary administration of FR-139317, a selective ETA receptor antagonist, was effective in attenuating the enhanced coronary vasoconstriction elicited by exogenously administered ET-1 at pathophysiological concentrations in this model. However, ET-1 was ineffective in inhibiting the coronary epicardial vasoconstriction associated with acetylcholine infusion. Similarly, short-term intracoronary administration of bosentan, a nonselective ET-receptor antagonist, did not affect the coronary epicardial vasoactive response to acetylcholine, although it did attenuate the severe coronary epicardial vasoconstrictor response to ET-1 after 10 weeks of high-cholesterol diet. These findings suggest that the ET receptor may not mediate the acute epicardial coronary vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. Previous studies in both experimental hypercholesterolemia in pig 8 and in humans with early atherosclerosis and coronary endothelial dysfunction 9 have demonstrated that circulating ET levels rise during intracoronary infusion of acetylcholine. In light of the potent coronary vasoconstrictor effect of ET, 1, 5, 14 the vasoconstrictor effect attained with acetylcholine in states of endothelial dysfunction has been presumed to be mediated, at least in part, by ET. 19 Coronary vasoconstriction in the steady state is mediated by both ETA and ETB receptors 20 -23 and is significantly attenuated by coinfusion with FR-139317, a selective ETA-receptor antagonist. 5 Thus, we hypothesized that FR-139317 would be effective in attenuating the vasoconstrictor response to acetylcholine in experimental hypercholesterolemia.
Our findings, however, demonstrate that the coronary vasoconstrictor response elicited by acetylcholine cannot be inhibited by short-term administration of a specific ETA antagonist. One could speculate that the selective ETA antagonist is ineffective in blocking the coronary vasoconstrictor actions of ET-1 in hypercholesterolemia because of the enhanced response to ET observed in hypercholesterolemia and atherosclerosis. 11 Indeed, our preliminary studies (phase I) confirmed that the coronary vasoconstrictor response to ET-1 at pathophysiological concentrations was enhanced in this model of experimental hypercholesterolemia. However, FR-139317 at the dosage used in this study (5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was successful in significantly attenuating this enhanced vasoconstrictor effect.
Coronary artery ET immunoreactivity is increased in experimental hypercholesterolemia in pigs 8 and in humans with atherosclerosis. 24 It is thus possible that acetylcholine causes a local increase in ET levels, which is of much greater magnitude than the rise in circulating levels. Indeed, circulating concentrations of ET have been shown to correlate poorly with local concentrations because ET is secreted primarily abluminally. 25, 26 Antagonists to ET receptors may be effective in blunting the actions of circulating or exogenously administered ET but may be less effective in inhibiting the local effects of elevated tissue ET levels, as previously reported by Krause and colleagues. 27 In addition, recent studies have indicated that the relative contribution of each ET receptor subtype (ie, ETA and ETB) may be different in pathophysiological states than in the steady state. In diet-induced hypercholesterolemia and atherosclerosis, there is diffuse upregulation of the ETB receptor. 28, 29 Furthermore, we 30 showed that in a canine experimental model of heart failure, which is associated with endothelial dysfunction, there is enhanced coronary vasoconstriction to ETB-receptor activation, albeit primarily at the level of the coronary microcirculation. It is thus possible that the contribution of endogenous ET to acetylcholine-induced coronary epicardial vasoconstriction in hypercholesterolemia is primarily mediated by ETB receptors, rather than by ETA receptors. However, this possibility is unlikely for two reasons: (1) in phase IV of the current study, we demonstrated that selective stimulation of the ETB receptor results in only mild coronary epicardial vasoconstriction, which was not altered after 10 weeks of high-cholesterol diet; and (2) the selective ETAreceptor antagonist FR-139317 significantly attenuated the coronary epicardial vasoconstrictor response to exogenously administered ET-1 in this experimental model of hypercholesterolemia. Accordingly, inhibition of the ETB receptor by bosentan in our study at a dose that attenuated the coronary epicardial vasoconstrictor response to ET-1 failed to affect the coronary epicardial vasoconstrictor response to acetylcholine. This does not negate a role for the ETB receptor in hypercholesterolemia. Indeed, Mathew et al 31 have demonstrated increased vasoconstriction elicited by ETB-receptor stimulation after 10 weeks of high-cholesterol diet, albeit only at the coronary microcirculation level.
Wang and colleagues 32 recently reported that administration of bosentan, a combined ETA-and ETB-receptor antagonist, preserved acetylcholine-induced endothelium-dependent vasodilation in an isolated rat model of myocardial injury and reperfusion, suggesting that inhibition of both ET receptors, ETA and ETB, may be required to attenuate the coronary vasoconstrictor effects of acetylcholine. In contrast, our studies with bosentan at a dose that induced mild systemic hypotension and blunted the coronary vasoconstrictor response to ET-1 failed to show any effect on the coronary response to acetylcholine. We cannot exclude the possibility that at higher doses of bosentan, an effect might have been attained. However, given the profound effects on systemic hemodynamics with higher doses of bosentan, it would be difficult to evaluate this possibility in vivo. In addition, bosentan may block the endothelial ETB-receptor-mediating vasodilation to a greater extent than the vascular smooth muscle ETBreceptor-mediating vasoconstriction, thus possibly exacerbating the vasoconstrictor response to acetylcholine.
Coronary vasoconstriction in response to acetylcholine is a complex process involving multiple vasoactive agents. 33 Endogenous agents causing vasoconstriction other than ET, such as angiotensin II 34, 35 and prostanoids, 36 are also activated by acetylcholine. Thus, it is possible that the inhibition of only one pathway is not sufficient in blunting acetylcholineinduced coronary vasoconstriction. Recently, ACE inhibitors have been shown to be effective in attenuating coronary endothelial dysfunction both in animal models 34, 35 and in humans. 37 The salutary effects of ACE inhibitors are attributed to their actions on different pathways, including the modulation of endogenous ET concentrations and activity. 38, 39 Drugs were given over a prolonged period in these studies, suggesting an antiatherogenic effect. 37 Hence, long-term inhibition of ET, blunting its atherogenic actions, 40, 41 may also be beneficial. Prolonged inhibition of ET may also be necessary to attenuate the time-dependent effects of elevated circulating and local levels of ET on acetylcholine-receptor production. 42 In addition, we recently demonstrated that the coronary artery nitric oxide pathway is attenuated in this porcine experimental model. 43 Thus, attenuating the vasoconstrictor response to acetylcholine may also require an increase in activity of vasodilators such as nitric oxide. Indeed, it is postulated that ACE inhibitors exert their salutary effect in part by increasing nitric oxide activity. 37 Thus, our findings should not be interpreted as negating a role for ET in mediating the vasoconstrictor effect attained with acetylcholine. Rather, they underscore the complexity of this response and hence the need for a therapeutic strategy involving the inhibition of multiple pathways.
In conclusion, the present studies demonstrate that acetylcholine-induced coronary vasoconstriction in a porcine model of hypercholesterolemia is not affected by short-term administration of ET-receptor antagonists. The mechanisms by which ET potentially affects acetylcholineinduced vasoconstriction in hypercholesterolemia remain to be determined.
